

October 2, 2017

**ONO PHARMACEUTICAL CO., LTD.**

President and Representative Director: Gyo Sagara

Code No: 4528 at the 1st section of the Tokyo Stock Exchange

Inquiries: Yukio Tani, Managing Director, Corporate Communications

**Notice of Completion of Acquisition of Own Shares**

(Acquisition of own shares under the Articles of Incorporation Provided in Article 165, Paragraph 2 of the Companies Act)

Osaka, Japan, October 2, 2017 - Ono Pharmaceutical Co., Ltd. (President, Representative Director and CEO, Gyo Sagara; “the Company”) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on June 13, 2017, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

## Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	15,896,100 shares
3. Aggregate amount of acquisition cost:	38,766,145,700 yen
4. Period of acquisition:	From June 14, 2017 to September 29, 2017 (execution base)
5. Method for acquisition:	Purchase on the Tokyo Stock Exchange

(Reference)

**1. Details of the resolution at the meeting of the Board of Directors held on June 13, 2017**

(1) Class of shares to be acquired:	Common stock of the Company
(2) Total number of shares to be acquired:	Up to 20 million shares (The percentage compared to the total number of the shares issued excluding own shares: 3.77%)
(3) Aggregate amount of acquisition cost:	Up to ¥50.0 billion
(4) Period of acquisition:	From June 14, 2017 to September 29, 2017